Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin and Midostaurin With Standard Induction for Newly Diagnosed FLT3-mutated AML
NCT03900949Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML). Primary endpoint: Maximum-tolerated dose at 42 days. Started Mar 2019; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03900949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900949.